- Telehealth Visits
Mark W. Cocalis, MD
Pediatric Critical Care • Pediatric CardiologyMark W. Cocalis, MD
Pediatric Critical Care • Pediatric Cardiology- Telehealth Visits
On this page
About me
Dr. Mark W. Cocalis is a pediatric cardiologist who provides a wide range of care for heart conditions. He is experienced in diagnosing fetal problems, caring for newborns and managing chronic conditions in older children. In his research, he has studied the use of stents – tiny tubes placed inside blood vessels to support blood flow – in treating newborn heart conditions.
Cocalis earned his medical degree from the David Geffen School of Medicine at UCLA. He completed a residency in pediatrics and a fellowship in pediatric cardiology at Ronald Reagan UCLA Medical Center.
Prior to joining UCSF, Cocalis was at Rady Children's Hospital – San Diego, where he headed the fetal echocardiography (heart ultrasound) service and heart transplant service. He also directed echocardiography, clinical services and the fellowship program in the cardiology division of Rady Children's Specialists of San Diego.
Education
Board Certification
- Pediatric Cardiology, American Board of Pediatrics
Fellowship
- University of California Los Angeles
Residency
- University of California Los Angeles
Internship
- University of California Los Angeles
School
- MD, University of California Los Angeles
Academic Title
- Health Sciences Clinical Professor
Care Keywords
Services
- Pediatric Critical Care
- Pediatric Cardiology
Locations
Provider Research Listing
Browse clinical trials and publications by this provider
Publications
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.
The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.